Photogen Reports PDT Treatmentof Ocular Melanoma Promising

KNOXVILLE, Tenn., Dec. 10 -- Photogen Technologies reported that the findings of a researcher working under an agreement with the company show complete eradication of ocular melanoma tumors in 84% of lab animals following a single treatment with Photogen's multi-photon excitation (MPE) technology. Lucy Young, a researcher at Massachusetts Eye and Ear Infirmary, presented her results at the Retina Society Annual Meeting in Maui, Hawaii.
The study was based on the fact that melanin precursors become extremely phototoxic in melanoma tumor cells when activated with certain light sources. Treatment with MPE technology led to the death of tumorous cells, while leaving healthy tissue unharmed. No additional phototoxic agents were administered to achieve these results. Current treatments for ocular melanoma may involve surgery, radiation or even removal of the eye, said Young. I am pleased to share these highly promising results that I've found using Photogen's MPE technology with my colleagues at the Retina Society meeting.